Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease

BACKGROUND: The risk of developing lung cancer is high in patients with interstitial lung disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are used for the treatment of non‐small cell lung cancer (NSCLC) in clinical practice; however, in patients with preexis...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanai, Osamu, Kim, Young Hak, Demura, Yoshiki, Kanai, Makiko, Ito, Tsuyoshi, Fujita, Kohei, Yoshida, Hironori, Akai, Masaya, Mio, Tadashi, Hirai, Toyohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026605/
https://www.ncbi.nlm.nih.gov/pubmed/29782069
http://dx.doi.org/10.1111/1759-7714.12759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026605/
https://www.ncbi.nlm.nih.gov/pubmed/29782069
http://dx.doi.org/10.1111/1759-7714.12759

Ejemplares similares